HIGHLIGHTS
- who: Caroline Burgard and collaborators from the Department of Nuclear Medicine, Saarland University, Homburg, Germany have published the article: Systemic Mastocytosis Treatment with Midostaurin: [18F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome, in the Journal: Diagnostics 2022, 12, 680. of /2022/
- what: The authors report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent 18 FFluorodeoxyglucose ([18 F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month therapy with midostaurin an established . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.